How can we improve our understanding of the progression of myeloma?

Irene Ghobrial, MD of the Dana-Farber Cancer Institute (DFCI), Boston, MA, discusses the progression of multiple myeloma (MM), which comes from precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma. It is not known, however, which patients will progress. +watch video

Dana-Farber Cancer Institute logo
Center for Prevention of Progression of Blood Cancers

© 2018 Dana-Farber Cancer Institute |  Terms of Use  |   Privacy Policy